Drug intelligence / Profile preview

GTX-201

Development stage: Discontinued
Lead developer: Grace Therapeutics
Modality: Small Molecules

Overview

GTX-201 is a small molecule drug initially developed by Grace Therapeutics (formerly Acasti Pharma). It was investigated primarily for the treatment of trigeminal neuralgia, a chronic pain condition affecting the trigeminal nerve in the face. The mechanism of action for GTX-201 has not been publicly defined or disclosed. Development reached Phase 1 clinical trials for trigeminal neuralgia but was subsequently discontinued for this indication. As of late 2024, preclinical development continues for an undisclosed indication under Grace Therapeutics[1][2].

Beyond the preview

Go deeper on GTX-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTX-201.

Explore the full profile